Eli Lilly: emergency authorization in Covid-19
(CercleFinance.com) - Eli Lilly has announce that the US FDA has granted emergency use authorization (EUA) for the of combination bamlanivimab (700 mg) and etesevimab (1400 mg), for the treatment of mild-to-moderate Covid-19.
The EUA is for patients 12 years of age and older who are at high risk of progression to severe disease and/or hospitalization. The combination should be injected as soon as possible after a positive test and within 10 days of the start of symptoms.
Eli Lilly, in collaboration with Amgen, plans to manufacture up to one million doses of etesevimab for administration with bamlanivimab by mid-2021. Over 250,000 doses will be manufactured throughout the first quarter.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The EUA is for patients 12 years of age and older who are at high risk of progression to severe disease and/or hospitalization. The combination should be injected as soon as possible after a positive test and within 10 days of the start of symptoms.
Eli Lilly, in collaboration with Amgen, plans to manufacture up to one million doses of etesevimab for administration with bamlanivimab by mid-2021. Over 250,000 doses will be manufactured throughout the first quarter.
Copyright (c) 2021 CercleFinance.com. All rights reserved.